Abstract Body

The clinical impact of viral blips on virologic failure and resistance development depends on the resistance barrier and forgiveness of the regimen. Here, we investigated the blip frequency and virologic outcomes of those experiencing blips among treatment-naïve people with HIV (PWH) initiating therapy on bictegravir (B)/emtricitabine (F)/tenofovir alafenamide (TAF), dolutegravir (DTG)/abacavir (ABC)/lamivudine (3TC), or DTG + F/TAF through 144 weeks of treatment in Studies 1489 and 1490.

PWH with at least one on-treatment post-baseline HIV RNA value were included in this analysis. HIV RNA and last observation carried forward (LOCF) outcome data through week 144 were used. A blip was an HIV RNA value ≥50 c/mL preceded and followed by HIV RNA <50 c/mL, after achieving confirmed suppression (two consecutive HIV RNA values <50 c/mL).

Of the 1240 participants with confirmed suppression, 143 (11.5%) had ≥1 blip through week 144 with similar blip frequencies between treatment arms (Table 1). An average of 1.3% of participants experienced blips per study visit, which was similar between treatment arms (Table 1). A total of 186 blip events occurred in the 143 individuals; 110 experienced a single blip and 33 experienced multiple blips. Of the 186 blips, 87 (46.8%) were low-level (50-199 c/mL) and 99 (53.2%) were ≥200 c/mL. The proportions of participants with blips <200 c/mL or ≥200 c/mL were similar between treatment arms (Table 1). Most with blips ≥200 c/mL had adherence ≤95% by pill count (69.2%), while those with blips <200 c/mL mostly had adherence >95% (63.1%) (Table 1). Of participants without blips, 98.7% (1083/1097) had HIV RNA <50 c/mL at week 144 or last visit vs. 91.0% (71/78) with blips ≥200 c/mL (p<0.01), or vs. 96.9% (63/65) with blips <200 c/mL (p=0.2). The 7 with blips ≥200 c/mL and HIV RNA ≥50 c/mL at week 144 were all on DTG-based regimens, and 6/7 had evidence of continued low adherence. Of the 21 individuals included in the overall resistance analysis population, 5 experienced blips and none had emergent resistance to study drugs (Table 1).

Viral blips were infrequent and similar among PWH treated with B/F/TAF, DTG/ABC/3TC, or DTG + F/TAF. Blips ≥200 c/mL but not <200 c/mL were associated with adherence ≤95%. High level blips of ≥200 c/mL were associated with lower suppression at week 144 due to poor adherence; however, none developed resistance on these 3-drug regimens with high barriers to resistance.